Full Press Release Details
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND #biotechnology--Vyome Holdings, Inc. (Nasdaq: HIND, “Vyome” or the “Company”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, reported financial results for the third quarter ended September 30, 2026, and provided a corporate update. Krishna Gupta, Chairman of Vyome Holdings, stated, “During the third quarter, Vyome continued to concentrate resources on the development of its lead program, VT-1953, while maintaining fina